RELISTOR

Relistor Adverse Events Reported to the FDA Over Time

How are Relistor adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Relistor, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Relistor is flagged as the suspect drug causing the adverse event.

Most Common Relistor Adverse Events Reported to the FDA

What are the most common Relistor adverse events reported to the FDA?

Drug Ineffective	37 (4.36%)
Abdominal Pain	35 (4.13%)
Nausea	28 (3.3%)
Vomiting	23 (2.71%)
Constipation	20 (2.36%)
Diarrhoea	15 (1.77%)
Hyperhidrosis	14 (1.65%)
Intestinal Perforation	14 (1.65%)
Chest Pain	13 (1.53%)
Dehydration	13 (1.53%)
Headache	13 (1.53%)
	Show More
Condition Aggravated	12 (1.42%)
Shock	11 (1.3%)
Abdominal Rigidity	10 (1.18%)
Needle Issue	10 (1.18%)
Fall	9 (1.06%)
Grand Mal Convulsion	9 (1.06%)
Pain	9 (1.06%)
Tachycardia	9 (1.06%)
Malaise	8 (.94%)
Abdominal Pain Upper	7 (.83%)
Blood Potassium Increased	7 (.83%)
Feeling Abnormal	7 (.83%)
Flushing	7 (.83%)
Heart Rate Increased	7 (.83%)
Hypertension	7 (.83%)
Hypotension	7 (.83%)
Incorrect Route Of Drug Administrat...	7 (.83%)
Renal Failure Acute	7 (.83%)
Sepsis	7 (.83%)
Abdominal Distension	6 (.71%)
Cardiac Failure Congestive	6 (.71%)
Coronary Artery Disease	6 (.71%)
Death	6 (.71%)
Drug Withdrawal Syndrome	6 (.71%)
Myocardial Infarction	6 (.71%)
Weight Decreased	6 (.71%)
Anxiety	5 (.59%)
Depressed Level Of Consciousness	5 (.59%)
Faecaloma	5 (.59%)
Intussusception	5 (.59%)
Large Intestine Perforation	5 (.59%)
Oedema Peripheral	5 (.59%)
Pain In Extremity	5 (.59%)
Septic Shock	5 (.59%)
Acute Hepatic Failure	4 (.47%)
Alanine Aminotransferase Increased	4 (.47%)
Aspartate Aminotransferase Increase...	4 (.47%)
Back Pain	4 (.47%)
Blood Bilirubin Increased	4 (.47%)
Blood Creatine Phosphokinase Increa...	4 (.47%)
Blood Creatinine Increased	4 (.47%)
Burning Sensation	4 (.47%)
Colpocele	4 (.47%)
Confusional State	4 (.47%)
Cyanosis	4 (.47%)
Decreased Appetite	4 (.47%)
Device Breakage	4 (.47%)
Disease Progression	4 (.47%)
Disseminated Intravascular Coagulat...	4 (.47%)
Drug Effect Decreased	4 (.47%)
Dyskinesia	4 (.47%)
Emotional Distress	4 (.47%)
Faecal Vomiting	4 (.47%)
Feeling Of Body Temperature Change	4 (.47%)
Hernia Repair	4 (.47%)
Irritability	4 (.47%)
Medical Diet	4 (.47%)
Mood Altered	4 (.47%)
Perforation Bile Duct	4 (.47%)
Syncope	4 (.47%)
Thrombocytopenia	4 (.47%)
Aphagia	3 (.35%)
Ascites	3 (.35%)
Blood Urea Increased	3 (.35%)
Blood Urine	3 (.35%)
Bone Marrow Disorder	3 (.35%)
Bradycardia	3 (.35%)
Choroiditis	3 (.35%)
Concomitant Disease Progression	3 (.35%)
Drug Dispensing Error	3 (.35%)
Hypophagia	3 (.35%)
Hypovolaemia	3 (.35%)
Injection Site Injury	3 (.35%)
Intentional Overdose	3 (.35%)
Intestinal Ischaemia	3 (.35%)
Intestinal Obstruction	3 (.35%)
Mental Status Changes	3 (.35%)
Muscle Spasms	3 (.35%)
Myoglobinaemia	3 (.35%)
No Therapeutic Response	3 (.35%)
Occult Blood	3 (.35%)
Peritonitis	3 (.35%)
Product Quality Issue	3 (.35%)
Protein Urine Present	3 (.35%)
Pyrexia	3 (.35%)
Rectal Haemorrhage	3 (.35%)
Suicide Attempt	3 (.35%)
Unevaluable Event	3 (.35%)
Visual Impairment	3 (.35%)
Abdominal Discomfort	2 (.24%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Relistor, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Relistor is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Relistor

What are the most common Relistor adverse events reported to the FDA?

Gastrointestinal Signs	131 (15.45%)
Therapeutic And Nontherapeutic Effe...	54 (6.37%)
Gastrointestinal Motility And Defec...	37 (4.36%)
Gastrointestinal Ulceration And Per...	24 (2.83%)
Neurological	24 (2.83%)
Cardiac Arrhythmias	21 (2.48%)
Infections - Pathogen Unspecified	21 (2.48%)
Decreased And Nonspecific Blood Pre...	20 (2.36%)
Skin Appendage Conditions	17 (2%)
Electrolyte And Fluid Balance Condi...	16 (1.89%)
Coronary Artery	15 (1.77%)
	Show More
Medication Errors	15 (1.77%)
Headaches	14 (1.65%)
Procedural And Device Related Injur...	14 (1.65%)
Renal And Urinary Tract Investigati...	13 (1.53%)
Administration Site Reactions	12 (1.42%)
Hepatobiliary	12 (1.42%)
Gastrointestinal Stenosis And Obstr...	11 (1.3%)
Injuries	11 (1.3%)
Seizures	11 (1.3%)
Cardiac And Vascular Investigations	10 (1.18%)
Musculoskeletal And Connective Tiss...	10 (1.18%)
Respiratory	10 (1.18%)
Gastrointestinal Hemorrhages	8 (.94%)
Mood Disorders	8 (.94%)
Peritoneal And Retroperitoneal Cond...	8 (.94%)
Renal Disorders	8 (.94%)
Vascular	8 (.94%)
Anxiety Disorders	7 (.83%)
Appetite And General Nutritional	7 (.83%)
Movement Disorders	7 (.83%)
Muscle	7 (.83%)
Vascular Hypertensive	7 (.83%)
Water, Electrolyte And Mineral	7 (.83%)
Epidermal And Dermal Conditions	6 (.71%)
Fatal Outcomes	6 (.71%)
Heart Failures	6 (.71%)
Lifestyle Issues	6 (.71%)
Physical Examination Topics	6 (.71%)
Hepatic And Hepatobiliary	5 (.59%)
Acid-base	4 (.47%)
Bile Duct	4 (.47%)
Cardiac Disorder Signs	4 (.47%)
Coagulopathies And Bleeding Diathes...	4 (.47%)
Deliria	4 (.47%)
Enzyme	4 (.47%)
Gastrointestinal Therapeutic Proced...	4 (.47%)
Platelet	4 (.47%)
Product Quality Issues	4 (.47%)
Respiratory And Mediastinal Neoplas...	4 (.47%)
Therapeutic Procedures And Supporti...	4 (.47%)
Uterine, Pelvic And Broad Ligament	4 (.47%)
Body Temperature Conditions	3 (.35%)
Gastrointestinal	3 (.35%)
Gastrointestinal Vascular Condition...	3 (.35%)
Hematological	3 (.35%)
Hematology Investigations	3 (.35%)
Metabolic, Nutritional And Blood Ga...	3 (.35%)
Miscellaneous And Site Unspecified ...	3 (.35%)
Ocular Infections, Irritations And ...	3 (.35%)
Psychiatric	3 (.35%)
Suicidal And Self-injurious Behavio...	3 (.35%)
Vision	3 (.35%)
Allergic Conditions	2 (.24%)
Arteriosclerosis, Stenosis, Vascula...	2 (.24%)
Depressed Mood Disorders	2 (.24%)
Gallbladder	2 (.24%)
Gastrointestinal Conditions	2 (.24%)
Gastrointestinal Neoplasms Malignan...	2 (.24%)
Glaucoma And Ocular Hypertension	2 (.24%)
Ocular Structural Change, Deposit A...	2 (.24%)
Pleural	2 (.24%)
Tissue	2 (.24%)
Tongue Conditions	2 (.24%)
Adrenal Gland	1 (.12%)
Anemias Nonhemolytic And Marrow Dep...	1 (.12%)
Bacterial Infectious	1 (.12%)
Bladder And Bladder Neck Disorders	1 (.12%)
Central Nervous System Vascular	1 (.12%)
Communication Disorders	1 (.12%)
Endocrine Investigations	1 (.12%)
Gastrointestinal Inflammatory Condi...	1 (.12%)
Glucose Metabolism Disorders	1 (.12%)
Metastases	1 (.12%)
Penile And Scrotal Disorders	1 (.12%)
Protein And Chemistry Analyses	1 (.12%)
Reproductive Tract	1 (.12%)
Respiratory And Pulmonary Investiga...	1 (.12%)
Spleen, Lymphatic And Reticulendoth...	1 (.12%)
Testicular And Epididymal	1 (.12%)
Urolithiases	1 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Relistor, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Relistor is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.